Telitacicept Evidence: Trial Results and Peer-Reviewed Publications
Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:
The clinical evidence base for Telitacicept comprises 39 peer-reviewed publications across 15 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Lupus Erythematosus, Systemic, Nephrotic Syndrome, Arthritis, Rheumatoid, and Glomerulonephritis, IGA. Most recent publication: The efficacy, safety, and pharmacokinetics/pharmacodynamics of telitacicept following efgartigimod in generalized myasthenia gravis: protocol of a randomized controlled trial., Front Immunol, 2025.
Top peer-reviewed publications
Curated set of pivotal-trial result papers and recent publications in high-tier journals.
- Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases.Zeng L, Yang K, Wu Y, et al. · J Autoimmun · 2024
- Non-immunosuppressive treatment for IgA nephropathy.Tunnicliffe DJ, Reid S, Craig JC, et al. · Cochrane Database Syst Rev · 2024
- The efficacy, safety, and pharmacokinetics/pharmacodynamics of telitacicept following efgartigimod in generalized myasthenia gravis: protocol of a randomized controlled trial.Li J, Zhang Y, Deng Y, et al. · Front Immunol · 2025
- Targeting B Cells and Plasma Cells in Glomerular Disease.Ahmad SB, Jefferson JA · J Am Soc Nephrol · 2025
- Gelsolin: a new biomarker of disease activity in SLE patients associated with HDL-c.Parra S, Heras M, Herrero P, et al. · Rheumatology (Oxford) · 2020
- Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study.Merrill JT, Wallace DJ, Wax S, et al. · Arthritis Rheumatol · 2019
- Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL.Gordon C, Wofsy D, Wax S, et al. · Arthritis Rheumatol · 2017
- A panel of urinary proteins predicts active lupus nephritis and response to rituximab treatment.Davies JC, Carlsson E, Midgley A, et al. · Rheumatology (Oxford) · 2021
Publications by year
1997–2025: 39 publications.
1997
1
2003
1
2004
1
2009
1
2010
1
2012
2
2013
2
2016
2
2017
1
2018
2
2019
4
2020
3
2021
6
2022
3
2023
4
2024
3
2025
2
Publications by indication
Lupus Erythematosus, Systemic (25)
- Glycosphingolipid Levels in Urine Extracellular Vesicles Enhance Prediction of Therapeutic Response in Lupus Nephritis.
- Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus.
- Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis.
- Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Response to Belimumab after Twelve Months of Therapy.
- Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.
Nephrotic Syndrome (10)
- Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria.
- Telitacicept for minimal change disease.
- The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study.
- Telitacicept for autoimmune nephropathy.
- Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease.
Arthritis, Rheumatoid (1)
- Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases.
Glomerulonephritis, IGA (1)
- Non-immunosuppressive treatment for IgA nephropathy.
Myasthenia Gravis (1)
- The efficacy, safety, and pharmacokinetics/pharmacodynamics of telitacicept following efgartigimod in generalized myasthenia gravis: protocol of a randomized controlled trial.
Lupus Nephritis (1)
- Targeting B Cells and Plasma Cells in Glomerular Disease.
Publications by journal
- Arthritis Rheum3 papers
- J Autoimmun2 papers
- Front Immunol2 papers
- J Am Soc Nephrol2 papers
- Semin Arthritis Rheum2 papers
- Rheumatology (Oxford)2 papers
- Arthritis Rheumatol2 papers
- Cochrane Database Syst Rev1 paper
- Kidney Int1 paper
- Eur J Pharm Sci1 paper
All Telitacicept publications (39)
2025 (2 papers)
- The efficacy, safety, and pharmacokinetics/pharmacodynamics of telitacicept following efgartigimod in generalized myasthenia gravis: protocol of a randomized controlled trial.Li J, Zhang Y, Deng Y, et al. · Front Immunol · 2025 · Derived
- Targeting B Cells and Plasma Cells in Glomerular Disease.Ahmad SB, Jefferson JA · J Am Soc Nephrol · 2025 · Derived
2024 (3 papers)
- Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases.Zeng L, Yang K, Wu Y, et al. · J Autoimmun · 2024 · Trial result
- Non-immunosuppressive treatment for IgA nephropathy.Tunnicliffe DJ, Reid S, Craig JC, et al. · Cochrane Database Syst Rev · 2024 · Derived
- Glycosphingolipid Levels in Urine Extracellular Vesicles Enhance Prediction of Therapeutic Response in Lupus Nephritis.Troyer B, Rodgers J, Wolf BJ, et al. · Metabolites · 2024 · Background
2023 (4 papers)
- Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria.Lv J, Liu L, Hao C, et al. · Kidney Int Rep · 2023 · Background
- Telitacicept for minimal change disease.Li S, Ding L, Yang YJ, et al. · Kaohsiung J Med Sci · 2023 · Background
- The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study.Chen R, Fu R, Lin Z, et al. · Lupus · 2023 · Background
- Telitacicept for autoimmune nephropathy.Cai J, Gao D, Liu D, et al. · Front Immunol · 2023 · Background
2022 (3 papers)
- Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease.Shi F, Xue R, Zhou X, et al. · Immunopharmacol Immunotoxicol · 2022 · Background
- Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus.Fan Y, Gao D, Zhang Z, et al. · Drugs Today (Barc) · 2022 · Background
- Telitacicept: First Approval.Dhillon S · Drugs · 2022 · Background
2021 (6 papers)
- Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis.Yao X, Ren Y, Zhao Q, et al. · Eur J Pharm Sci · 2021 · Background
- Incidence and Relapse of Idiopathic Nephrotic Syndrome: Meta-analysis.Veltkamp F, Rensma LR, Bouts AHM, et al. · Pediatrics · 2021 · Background
- Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Response to Belimumab after Twelve Months of Therapy.Piantoni S, Regola F, Masneri S, et al. · Front Pharmacol · 2021 · Background
- Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.Pedrosa L, Fernández-Miranda I, Pérez-Callejo D, et al. · Sci Rep · 2021 · Background
- Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment.Davies JC, Midgley A, Carlsson E, et al. · RMD Open · 2021 · Background
- A panel of urinary proteins predicts active lupus nephritis and response to rituximab treatment.Davies JC, Carlsson E, Midgley A, et al. · Rheumatology (Oxford) · 2021 · Background
2020 (3 papers)
- Lymphocyte phenotype and its application to precision medicine in systemic autoimmune diseases✰.Tanaka Y, Kubo S, Miyagawa I, et al. · Semin Arthritis Rheum · 2020 · Background
- Gelsolin: a new biomarker of disease activity in SLE patients associated with HDL-c.Parra S, Heras M, Herrero P, et al. · Rheumatology (Oxford) · 2020 · Background
- Circulating microRNAs as potential biomarkers for monitoring the response to in vivo treatment with Rituximab in systemic lupus erythematosus patients.Cecchi I, Perez-Sanchez C, Sciascia S, et al. · Autoimmun Rev · 2020 · Background
2019 (4 papers)
- Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study.Merrill JT, Wallace DJ, Wax S, et al. · Arthritis Rheumatol · 2019 · Background
- Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study.Iaccarino L, Andreoli L, Bocci EB, et al. · J Autoimmun · 2019 · Background
- Lessons learned from the failure of several recent trials with biologic treatment in systemic lupus erythematosus.Hruskova Z, Tesar V · Expert Opin Biol Ther · 2019 · Background
- NMR-Based Serum Metabolomics Reveals Reprogramming of Lipid Dysregulation Following Cyclophosphamide-Based Induction Therapy in Lupus Nephritis.Guleria A, Phatak S, Dubey D, et al. · J Proteome Res · 2019 · Background
2018 (2 papers)
- Diagnostic and prognostic tests in systemic lupus erythematosus.Vasquez-Canizares N, Wahezi D, Putterman C, et al. · Best Pract Res Clin Rheumatol · 2018 · Background
- Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): A systematic review.Pirone C, Mendoza-Pinto C, van der Windt DA, et al. · Semin Arthritis Rheum · 2018 · Background
2017 (1 paper)
- Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL.Gordon C, Wofsy D, Wax S, et al. · Arthritis Rheumatol · 2017 · Background
2016 (2 papers)
- Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus.Shu W, Guan S, Yang X, et al. · Br J Clin Pharmacol · 2016 · Background
- A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).Kalunian KC, Merrill JT, Maciuca R, et al. · Ann Rheum Dis · 2016 · Background
2013 (2 papers)
- B cell biomarkers of rituximab responses in systemic lupus erythematosus.Vital EM, Dass S, Buch MH, et al. · Arthritis Rheum · 2013 · Background
- Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.McBride JM, Jiang J, Abbas AR, et al. · Arthritis Rheum · 2013 · Background
2012 (2 papers)
- The discovery and development of belimumab: the anti-BLyS-lupus connection.Stohl W, Hilbert DM · Nat Biotechnol · 2012 · Background
- Identification of urinary metabolites that distinguish membranous lupus nephritis from proliferative lupus nephritis and focal segmental glomerulosclerosis.Romick-Rosendale LE, Brunner HI, Bennett MR, et al. · Arthritis Res Ther · 2012 · Background
2010 (1 paper)
- Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.Merrill JT, Neuwelt CM, Wallace DJ, et al. · Arthritis Rheum · 2010 · Background
2009 (1 paper)
- Biomarkers of lupus nephritis determined by serial urine proteomics.Zhang X, Jin M, Wu H, et al. · Kidney Int · 2009 · Background
2004 (1 paper)
- Is there really an increase in non-minimal change nephrotic syndrome in children?Filler G, Young E, Geier P, et al. · Am J Kidney Dis · 2004 · Background
2003 (1 paper)
- Nephrotic syndrome in childhood.Eddy AA, Symons JM · Lancet · 2003 · Background
1997 (1 paper)
- Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children.Tarshish P, Tobin JN, Bernstein J, et al. · J Am Soc Nephrol · 1997 · Background
Sources and methodology
- Publications:
ctgov.study_references(PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference typesRESULT,DERIVED, andBACKGROUND. - Per-arm outcome values:
ctgov.outcome_measurementsjoined toctgov.design_outcomeswhereoutcome_type = 'PRIMARY', restricted to phasePHASE3andPHASE2/PHASE3. - Publication metadata (title, journal, year, authors): PubMed E-utilities
efetch.fcgi - Data freshness: Thu, 14 May 2026 21:51:43 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).